Effect of metformin on survival rate in experimental sepsis

Diabetes and Metabolism

Volumn 32, Issue 2, 2006, Pages 147-150

  Gras, V ^a   Bouffandeau, B ^b   Montravers, Ph ^c   Lalau, J D ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b CENTRE HOSPITALIER   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

Lactic acidosis; Metformin; Sepsis; Type 2 diabetes

Indexed keywords

METFORMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; CLINICAL PRACTICE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; ESCHERICHIA COLI; INOCULATION; KAPLAN MEIER METHOD; LETHAL DOSE; LOG RANK TEST; MORTALITY; MOUSE; NONHUMAN; SEPSIS; STATISTICAL ANALYSIS; SURVIVAL RATE;

EID: 33645979957     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70261-6     Document Type: Article

References (20)

1. Sirtori C, Pasik C. Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. Pharmacol Res 1994;30:187-228
2. Misbin R, Green L, Stadel B, Gueriguian J, Guffi A, Flemming G. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998;338:265-6
3. Chang C, Chen YC, Fang JT, Huang CC. Metformin-associated lactic acidosis: case reports and literature review. J Nephrol 2000;15:398-402
4. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2003;163:2594-602
5. Lalau JD, Lacroix C, Compagnon P, et al. Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care 1995;18:779-84
6. Lalau JD, Race JM. Metformin and lactic acidosis in diabetic humans. Diabetes Obesity Metab 2000;2:131-7
7. Montravers P, Andremont A, Massis L, Carbon C. Investigation of the potential role of Enterococcus faecalis in the pathophysiology of experimental peritonitis. J Infect Dis 1994;169:821-30
8. Dupont H, Montravers P, Mohler J, Carbon C. Disparate findings on the role of virulence factors of Enterococcus faecalis in mouse and rat models of peritonitis. Infect Immun 1998;169:2570-5
9. Ike Y, Hashimoto H, Clewell D. Hemolysin of Steptococcus faecalis subspecies zymogenes contributes to virulence in mice. Infect Immun 1984;15:528-30
10. Lacroix C, Danger P, Wojciechowski F. Microdosage de la metformine plasmatique et intra-érythrocytaire par chromatographie en phase liquide. Ann Clin (Paris) 1991;49:98-101
11. Sterne J. Pharmacology and mode of action of hypoglycaemic guanidine derivates. In: Campell IW, ed, Oral hypoglycaemic agents. London: Academic Press 1969,193-245
12. Sirtori C, Franceschini G, Galli-Kienle M, Cighette G, Bondioli A, Conti F. Disposition of metformin (N, N-dimethylbiguanide) in man. Clin Pharmacol Ther 1978;24:683-93
13. Scheen AJ. Clinical Pharmacokinetics of metformin. Clin Pharmacokinet 1996;30:359-71
14. Wilcock C, Balley CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 1994;24:49-57.
15. Muller M, Gorter KJ, Hak E, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 2005;41:281-8
16. Laupland KB, Gregson DB, Zygun DA, Doig CJ, Mortis G, Church DL. Severe bloodstream infections: a population-based assessment. Crit Care Med 2004;32:992-7
17. Leverve X. Lactic acidosis. A new insight? Minerva Anestesiol 1999;65:205-9
18. + ATPase activity and raised lactate concentrations in septic shock: a prospective study. Lancet 2005;365:871-5
19. Wiernsperger NF. Metformin: intrinsic vasculoprotective properties. Diabetes Technol Ther 2000;2:259-72
20. UK Prospective Diabetes Study (UKPDS) group. Effect of intensive blood-glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65